Right ventricular enlargement predicts responsiveness to tolvaptan in congestive heart failure patients with reduced ejection fraction

Right ventricular enlargement predicts responsiveness to tolvaptan in congestive heart failure patients with reduced ejection fraction

Background: Tolvaptan is a vasopressin type 2 receptor antagonist used in heart failure (HF) with refractory diuretic resistance. However, since tolvaptan is also ineffective in some HF patients with reduced ejection fraction (HFrEF), the identification of responders is important. Methods: The study...

Full description

Bibliographic Details
Main Authors: Shinichi Nonin, Shinichi Iwata, Asahiro Ito, Soichiro Tamura, Ryoko Kitada, Yu Kawai, Sera Ishikawa, Atsushi Doi, Akihisa Hanatani, Minoru Yoshiyama
Format: Article
Language:English
Published: Elsevier 2018-12-01
Series:International Journal of Cardiology: Heart & Vasculature
Online Access:http://www.sciencedirect.com/science/article/pii/S2352906718301076

Internet

http://www.sciencedirect.com/science/article/pii/S2352906718301076

Similar Items